Video

When is the right time for genetic testing in prostate cancer?

Current Time 0:00
Duration 1:13
Loaded: 0%
Stream Type LIVE
Remaining Time 1:13
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Samantha E. Greenberg, MS, MPH, CGC, a genetic counselor at the Huntsman Cancer Institute, on when to discuss genetic testing with prostate cancer patients.

    Related Videos
    Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
    Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
    Paul Sieber, MD, on the future of genetic testing in prostate cancer
    Paul Sieber, MD, on the future of genetic testing in prostate cancer
    Daniel Kwon, MD, answers a question during a Zoom video interview
    Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
    Tim Richardson, MD, on genetic testing in the era of targeted therapies
    Tim Richardson, MD, on genetic testing in the era of targeted therapies
    DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
    Discussing germline testing for prostate cancer with veterans
    Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
    Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
    Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
    Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
    DNA molecules | Image Credit: © vitstudio - stock.adobe.com
    Germline testing study’s implications for veteran access to prostate cancer treatments
    Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
    Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
    Daniel Kwon, MD, answers a question during a Zoom video interview
    Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
    Related Content
    Study shows value of precision-based approaches in prostate cancer
    May 19th 2025

    Study shows value of precision-based approaches in prostate cancer

    Hannah Clarke
    The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
    Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
    February 25th 2025

    Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

    Hannah Clarke
    Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
    Pathogenic variants of WNT9B gene linked to hereditary prostate cancer
    January 29th 2025

    Pathogenic variants of WNT9B gene linked to hereditary prostate cancer

    Hannah Clarke
    WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
    Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
    January 22nd 2025

    Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

    Hannah Clarke
    "[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
    3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
    December 24th 2024

    Quiz: CUA guidelines on specimen and timing considerations with genetic testing

    Patrick Campbell
    Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
    NCCN reaffirms Prolaris’ prognostic value in prostate cancer
    December 18th 2024

    NCCN reaffirms Prolaris’ prognostic value in prostate cancer

    Hannah Clarke
    The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
    © 2025 MJH Life Sciences

    All rights reserved.